메뉴 건너뛰기




Volumn 16, Issue 8, 2015, Pages 1185-1194

Anagrelide hydrochloride and ruxolitinib for treatment of polycythemia vera

Author keywords

Anagrelide; Hydroxyurea; JAK inhibitor; JAK2V617F; Myeloproliferative neoplasm; Polycythemia vera; Ruxolitinib

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA INTERFERON; ANAGRELIDE; BUSULFAN; HYDROXYUREA; PEGINTERFERON; RUXOLITINIB; ANTITHROMBOCYTIC AGENT; FIBRINOLYTIC AGENT; MACROGOL DERIVATIVE; PYRAZOLE DERIVATIVE; QUINAZOLINE DERIVATIVE;

EID: 84929224332     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2015.1036029     Document Type: Review
Times cited : (5)

References (55)
  • 1
    • 0035079648 scopus 로고    scopus 로고
    • Epidemiology of the myeloproliferative disorders: Essential thrombocythaemia, polycythaemia vera and idiopathic myelofibrosis
    • Kutti J, Ridell B. Epidemiology of the myeloproliferative disorders: essential thrombocythaemia, polycythaemia vera and idiopathic myelofibrosis. Pathol Biol (Paris) 2001;49(2):164-6
    • (2001) Pathol Biol (Paris) , vol.49 , Issue.2 , pp. 164-166
    • Kutti, J.1    Ridell, B.2
  • 2
    • 0026649984 scopus 로고
    • High incidence of myeloproliferative disorders in Ashkenazi Jews in northern Israel
    • Chaiter Y, Brenner B, Aghai E, et al. High incidence of myeloproliferative disorders in Ashkenazi Jews in northern Israel. Leuk Lymphoma 1992;7(3):251-5
    • (1992) Leuk Lymphoma , vol.7 , Issue.3 , pp. 251-255
    • Chaiter, Y.1    Brenner, B.2    Aghai, E.3
  • 3
    • 0026069267 scopus 로고
    • Mortality patterns among petroleum refinery and chemical plant workers
    • Marsh GM, Enterline PE, McCraw D. Mortality patterns among petroleum refinery and chemical plant workers. Am J Ind Med 1991;19(1):29-42
    • (1991) Am J Ind Med , vol.19 , Issue.1 , pp. 29-42
    • Marsh, G.M.1    Enterline, P.E.2    McCraw, D.3
  • 4
    • 84879104781 scopus 로고    scopus 로고
    • Age-related differences in disease characteristics and clinical outcomes in polycythemia vera
    • Stein BL, Saraf S, Sobol U, et al. Age-related differences in disease characteristics and clinical outcomes in polycythemia vera. Leuk Lymphoma 2013;54(9):1989-95
    • (2013) Leuk Lymphoma , vol.54 , Issue.9 , pp. 1989-1995
    • Stein, B.L.1    Saraf, S.2    Sobol, U.3
  • 5
    • 84883742082 scopus 로고    scopus 로고
    • Survival and prognosis among 1545 patients with contemporary polycythemia vera: An international study
    • Tefferi A, Rumi E, Finazzi G, et al. Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study. Leukemia 2013;27(9):1874-81
    • (2013) Leukemia , vol.27 , Issue.9 , pp. 1874-1881
    • Tefferi, A.1    Rumi, E.2    Finazzi, G.3
  • 6
    • 17844383458 scopus 로고    scopus 로고
    • A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera
    • James C, Ugo V, Le Couedic JP, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005;434(7037):1144-8
    • (2005) Nature , vol.434 , Issue.7037 , pp. 1144-1148
    • James, C.1    Ugo, V.2    Le Couedic, J.P.3
  • 7
    • 21344467318 scopus 로고    scopus 로고
    • Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders
    • Jones AV, Kreil S, Zoi K, et al. Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders. Blood 2005;106(6):2162-8
    • (2005) Blood , vol.106 , Issue.6 , pp. 2162-2168
    • Jones, A.V.1    Kreil, S.2    Zoi, K.3
  • 8
    • 33846660947 scopus 로고    scopus 로고
    • JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis
    • Scott LM, Tong W, Levine RL, et al. JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N Engl J Med 2007;356(5):459-68
    • (2007) N Engl J Med , vol.356 , Issue.5 , pp. 459-468
    • Scott, L.M.1    Tong, W.2    Levine, R.L.3
  • 9
    • 84919467186 scopus 로고    scopus 로고
    • Presence of calreticulin mutations in JAK2-negative polycythemia vera
    • Broseus J, Park JH, Carillo S, et al. Presence of calreticulin mutations in JAK2-negative polycythemia vera. Blood 2014;124(26):3964-6
    • (2014) Blood , vol.124 , Issue.26 , pp. 3964-3966
    • Broseus, J.1    Park, J.H.2    Carillo, S.3
  • 10
    • 34548042964 scopus 로고    scopus 로고
    • Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: Recommendations from an ad hoc international expert panel
    • Tefferi A, Thiele J, Orazi A, et al. Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel. Blood 2007;110(4):1092-7
    • (2007) Blood , vol.110 , Issue.4 , pp. 1092-1097
    • Tefferi, A.1    Thiele, J.2    Orazi, A.3
  • 11
    • 84893964717 scopus 로고    scopus 로고
    • Masked polycythemia vera diagnosed according to WHO and BCSH classification
    • Barbui T, Thiele J, Carobbio A, et al. Masked polycythemia vera diagnosed according to WHO and BCSH classification. Am J Hematol 2014;89(2):199-202
    • (2014) Am J Hematol , vol.89 , Issue.2 , pp. 199-202
    • Barbui, T.1    Thiele, J.2    Carobbio, A.3
  • 12
    • 34548152255 scopus 로고    scopus 로고
    • Amendment to the guideline for diagnosis and investigation of polycythaemia/erythrocytosis
    • McMullin MF, Reilly JT, Campbell P, et al. Amendment to the guideline for diagnosis and investigation of polycythaemia/erythrocytosis. Br J Haematol 2007;138(6):821-2
    • (2007) Br J Haematol , vol.138 , Issue.6 , pp. 821-822
    • McMullin, M.F.1    Reilly, J.T.2    Campbell, P.3
  • 13
    • 84904067758 scopus 로고    scopus 로고
    • An overview on CALR and CSF3R mutations and a proposal for revision of WHO diagnostic criteria for myeloproliferative neoplasms
    • Tefferi A, Thiele J, Vannucchi AM, et al. An overview on CALR and CSF3R mutations and a proposal for revision of WHO diagnostic criteria for myeloproliferative neoplasms. Leukemia 2014;28(7):1407-13
    • (2014) Leukemia , vol.28 , Issue.7 , pp. 1407-1413
    • Tefferi, A.1    Thiele, J.2    Vannucchi, A.M.3
  • 14
    • 84887373344 scopus 로고    scopus 로고
    • Evaluation of WHO criteria for diagnosis of polycythemia vera: A prospective analysis
    • Silver RT, Chow W, Orazi A, et al. Evaluation of WHO criteria for diagnosis of polycythemia vera: a prospective analysis. Blood 2013;122(11):1881-6
    • (2013) Blood , vol.122 , Issue.11 , pp. 1881-1886
    • Silver, R.T.1    Chow, W.2    Orazi, A.3
  • 15
    • 34249949626 scopus 로고    scopus 로고
    • Thrombosis in myeloproliferative disorders: Prevalence, prognostic factors, and the role of leukocytes and JAK2V617F
    • Tefferi A, Elliott M. Thrombosis in myeloproliferative disorders: prevalence, prognostic factors, and the role of leukocytes and JAK2V617F. Semin Thromb Hemost 2007;33(4):313-20
    • (2007) Semin Thromb Hemost , vol.33 , Issue.4 , pp. 313-320
    • Tefferi, A.1    Elliott, M.2
  • 16
    • 84871746842 scopus 로고    scopus 로고
    • Cardiovascular events and intensity of treatment in polycythemia vera
    • Marchioli R, Finazzi G, Specchia G, et al. Cardiovascular events and intensity of treatment in polycythemia vera. N Engl J Med 2013;368(1):22-33
    • (2013) N Engl J Med , vol.368 , Issue.1 , pp. 22-33
    • Marchioli, R.1    Finazzi, G.2    Specchia, G.3
  • 17
    • 0346727336 scopus 로고    scopus 로고
    • Efficacy and safety of low-dose aspirin in polycythemia vera
    • Landolfi R, Marchioli R, Kutti J, et al. Efficacy and safety of low-dose aspirin in polycythemia vera. N Engl J Med 2004;350(2):114-24
    • (2004) N Engl J Med , vol.350 , Issue.2 , pp. 114-124
    • Landolfi, R.1    Marchioli, R.2    Kutti, J.3
  • 18
    • 79551491928 scopus 로고    scopus 로고
    • Philadelphia-negative classical myeloproliferative neoplasms: Critical concepts and management recommendations from European LeukemiaNet
    • Barbui T, Barosi G, Birgegard G, et al. Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. J Clin Oncol 2011;29(6):761-70
    • (2011) J Clin Oncol , vol.29 , Issue.6 , pp. 761-770
    • Barbui, T.1    Barosi, G.2    Birgegard, G.3
  • 19
    • 43949103121 scopus 로고    scopus 로고
    • Life expectancy and prognostic factors in the classic BCR/ABL-negative myeloproliferative disorders
    • Cervantes F, Passamonti F, Barosi G. Life expectancy and prognostic factors in the classic BCR/ABL-negative myeloproliferative disorders. Leukemia 2008;22(5):905-14
    • (2008) Leukemia , vol.22 , Issue.5 , pp. 905-914
    • Cervantes, F.1    Passamonti, F.2    Barosi, G.3
  • 20
    • 84874959297 scopus 로고    scopus 로고
    • Polycythemia vera: Current pharmacotherapy and future directions
    • Hensley B, Geyer H, Mesa R. Polycythemia vera: current pharmacotherapy and future directions. Expert Opin Pharmacother 2013;14(5):609-17
    • (2013) Expert Opin Pharmacother , vol.14 , Issue.5 , pp. 609-617
    • Hensley, B.1    Geyer, H.2    Mesa, R.3
  • 21
    • 0031041044 scopus 로고    scopus 로고
    • From efficacy to safety: A Polycythemia Vera Study group report on hydroxyurea in patients with polycythemia vera
    • Fruchtman SM, Mack K, Kaplan ME, et al. From efficacy to safety: a Polycythemia Vera Study group report on hydroxyurea in patients with polycythemia vera. Semin Hematol 1997;34(1):17-23
    • (1997) Semin Hematol , vol.34 , Issue.1 , pp. 17-23
    • Fruchtman, S.M.1    Mack, K.2    Kaplan, M.E.3
  • 22
    • 84859922985 scopus 로고    scopus 로고
    • Hydroxyurea-related toxicity in 3,411 patients with Ph'-negative MPN
    • Antonioli E, Guglielmelli P, Pieri L, et al. Hydroxyurea-related toxicity in 3,411 patients with Ph'-negative MPN. Am J Hematol 2012;87(5):552-4
    • (2012) Am J Hematol , vol.87 , Issue.5 , pp. 552-554
    • Antonioli, E.1    Guglielmelli, P.2    Pieri, L.3
  • 23
    • 77649227181 scopus 로고    scopus 로고
    • A unified definition of clinical resistance and intolerance to hydroxycarbamide in polycythaemia vera and primary myelofibrosis: Results of a European LeukemiaNet (ELN) consensus process
    • Barosi G, Birgegard G, Finazzi G, et al. A unified definition of clinical resistance and intolerance to hydroxycarbamide in polycythaemia vera and primary myelofibrosis: results of a European LeukemiaNet (ELN) consensus process. Br J Haematol 2010;148(6):961-3
    • (2010) Br J Haematol , vol.148 , Issue.6 , pp. 961-963
    • Barosi, G.1    Birgegard, G.2    Finazzi, G.3
  • 24
    • 66549086134 scopus 로고    scopus 로고
    • Response criteria for essential thrombocythemia and polycythemia vera: Result of a European LeukemiaNet consensus conference
    • Barosi G, Birgegard G, Finazzi G, et al. Response criteria for essential thrombocythemia and polycythemia vera: result of a European LeukemiaNet consensus conference. Blood 2009;113(20):4829-33
    • (2009) Blood , vol.113 , Issue.20 , pp. 4829-4833
    • Barosi, G.1    Birgegard, G.2    Finazzi, G.3
  • 25
    • 79959203501 scopus 로고    scopus 로고
    • Treatment-related risk factors for transformation to acute myeloid leukemia and myelodysplastic syndromes in myeloproliferative neoplasms
    • Bjorkholm M, Derolf AR, Hultcrantz M, et al. Treatment-related risk factors for transformation to acute myeloid leukemia and myelodysplastic syndromes in myeloproliferative neoplasms. J Clin Oncol 2011;29(17):2410-15
    • (2011) J Clin Oncol , vol.29 , Issue.17 , pp. 2410-2415
    • Bjorkholm, M.1    Derolf, A.R.2    Hultcrantz, M.3
  • 26
    • 80053945428 scopus 로고    scopus 로고
    • Treatment of polycythemia vera with hydroxyurea and pipobroman: Final results of a randomized trial initiated in 1980
    • Kiladjian JJ, Chevret S, Dosquet C, et al. Treatment of polycythemia vera with hydroxyurea and pipobroman: final results of a randomized trial initiated in 1980. J Clin Oncol 2011;29(29):3907-13
    • (2011) J Clin Oncol , vol.29 , Issue.29 , pp. 3907-3913
    • Kiladjian, J.J.1    Chevret, S.2    Dosquet, C.3
  • 27
    • 79952980528 scopus 로고    scopus 로고
    • Hydroxycarbamide: A user's guide for chronic myeloproliferative disorders
    • Spivak JL, Hasselbalch H. Hydroxycarbamide: a user's guide for chronic myeloproliferative disorders. Expert Rev Anticancer Ther 2011;11(3):403-14
    • (2011) Expert Rev Anticancer Ther , vol.11 , Issue.3 , pp. 403-414
    • Spivak, J.L.1    Hasselbalch, H.2
  • 28
    • 0016492795 scopus 로고
    • Comparative distribution and embryotoxicity of hydroxyurea in pregnant rats and rhesus monkeys
    • Wilson JG, Scott WJ, Ritter EJ, et al. Comparative distribution and embryotoxicity of hydroxyurea in pregnant rats and rhesus monkeys. Teratology 1975;11(2):169-78
    • (1975) Teratology , vol.11 , Issue.2 , pp. 169-178
    • Wilson, J.G.1    Scott, W.J.2    Ritter, E.J.3
  • 29
    • 46849120215 scopus 로고    scopus 로고
    • Influence of sickle cell disease and treatment with hydroxyurea on sperm parameters and fertility of human males
    • Berthaut I, Guignedoux G, Kirsch-Noir F, et al. Influence of sickle cell disease and treatment with hydroxyurea on sperm parameters and fertility of human males. Haematologica 2008;93(7):988-93
    • (2008) Haematologica , vol.93 , Issue.7 , pp. 988-993
    • Berthaut, I.1    Guignedoux, G.2    Kirsch-Noir, F.3
  • 30
    • 56249104095 scopus 로고    scopus 로고
    • Interferon-alpha therapy in bcr-abl-negative myeloproliferative neoplasms
    • Kiladjian JJ, Chomienne C, Fenaux P. Interferon-alpha therapy in bcr-abl-negative myeloproliferative neoplasms. Leukemia 2008;22(11):1990-8
    • (2008) Leukemia , vol.22 , Issue.11 , pp. 1990-1998
    • Kiladjian, J.J.1    Chomienne, C.2    Fenaux, P.3
  • 31
    • 84908022970 scopus 로고    scopus 로고
    • Interferon alpha-2b gains high sustained response therapy for advanced essential thrombocythemia and polycythemia vera with JAK2V617F positive mutation
    • Huang BT, Zeng QC, Zhao WH. Interferon alpha-2b gains high sustained response therapy for advanced essential thrombocythemia and polycythemia vera with JAK2V617F positive mutation. Leuk Res 2014;38(10):1177-83
    • (2014) Leuk Res , vol.38 , Issue.10 , pp. 1177-1183
    • Huang, B.T.1    Zeng, Q.C.2    Zhao, W.H.3
  • 32
    • 33746307253 scopus 로고    scopus 로고
    • Long-term effects of the treatment of polycythemia vera with recombinant interferon-alpha
    • Silver RT. Long-term effects of the treatment of polycythemia vera with recombinant interferon-alpha. Cancer 2006;107(3):451-8
    • (2006) Cancer , vol.107 , Issue.3 , pp. 451-458
    • Silver, R.T.1
  • 33
    • 84867261125 scopus 로고    scopus 로고
    • Experience with pegylated interferon alpha-2a in advanced myeloproliferative neoplasms in an international cohort of 118 patients
    • Gowin K, Thapaliya P, Samuelson J, et al. Experience with pegylated interferon alpha-2a in advanced myeloproliferative neoplasms in an international cohort of 118 patients. Haematologica 2012;97(10):1570-3
    • (2012) Haematologica , vol.97 , Issue.10 , pp. 1570-1573
    • Gowin, K.1    Thapaliya, P.2    Samuelson, J.3
  • 34
    • 81255210738 scopus 로고    scopus 로고
    • A new era for IFNalpha in the treatment of Philadelphianegative chronic myeloproliferative neoplasms
    • Hasselbalch HC. A new era for IFNalpha in the treatment of Philadelphianegative chronic myeloproliferative neoplasms. Expert Rev Hematol 2011;4(6):637-55
    • (2011) Expert Rev Hematol , vol.4 , Issue.6 , pp. 637-655
    • Hasselbalch, H.C.1
  • 36
    • 54049141336 scopus 로고    scopus 로고
    • Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera
    • Kiladjian JJ, Cassinat B, Chevret S, et al. Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera. Blood 2008;112(8):3065-72
    • (2008) Blood , vol.112 , Issue.8 , pp. 3065-3072
    • Kiladjian, J.J.1    Cassinat, B.2    Chevret, S.3
  • 37
    • 73949090770 scopus 로고    scopus 로고
    • Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera
    • Quintas-Cardama A, Kantarjian H, Manshouri T, et al. Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera. J Clin Oncol 2009;27(32):5418-24
    • (2009) J Clin Oncol , vol.27 , Issue.32 , pp. 5418-5424
    • Quintas-Cardama, A.1    Kantarjian, H.2    Manshouri, T.3
  • 38
    • 8544265328 scopus 로고    scopus 로고
    • Efficacy and safety of human leucocyte interferon-alpha treatment in patients younger than 60 years of age with polycythaemia vera
    • Stasi R, Brunetti M, Bussa S, et al. Efficacy and safety of human leucocyte interferon-alpha treatment in patients younger than 60 years of age with polycythaemia vera. J Intern Med 1997;242(2):143-7
    • (1997) J Intern Med , vol.242 , Issue.2 , pp. 143-147
    • Stasi, R.1    Brunetti, M.2    Bussa, S.3
  • 39
    • 0031978967 scopus 로고    scopus 로고
    • Role of human leukocyte interferonalpha in the treatment of patients with polycythemia vera
    • Stasi R, Venditti A, Del Poeta G, et al. Role of human leukocyte interferonalpha in the treatment of patients with polycythemia vera. Am J Med Sci 1998;315(4):237-41
    • (1998) Am J Med Sci , vol.315 , Issue.4 , pp. 237-241
    • Stasi, R.1    Venditti, A.2    Del Poeta, G.3
  • 40
    • 0023946455 scopus 로고
    • Anagrelide: A new drug for treating thrombocytosis
    • Silverstein MN, Petitt RM, Solberg LA Jr, et al. Anagrelide: a new drug for treating thrombocytosis. N Engl J Med 1988;318(20):1292-4
    • (1988) N Engl J Med , vol.318 , Issue.20 , pp. 1292-1294
    • Silverstein, M.N.1    Petitt, R.M.2    Solberg, L.A.3
  • 41
    • 14744274434 scopus 로고    scopus 로고
    • Anagrelide: Analysis of long-term efficacy, safety and leukemogenic potential in myeloproliferative disorders
    • Fruchtman SM, Petitt RM, Gilbert HS, et al. Anagrelide: analysis of long-term efficacy, safety and leukemogenic potential in myeloproliferative disorders. Leuk Res 2005;29(5):481-91
    • (2005) Leuk Res , vol.29 , Issue.5 , pp. 481-491
    • Fruchtman, S.M.1    Petitt, R.M.2    Gilbert, H.S.3
  • 42
    • 31444454549 scopus 로고    scopus 로고
    • Anagrelide: A review of its use in the management of essential thrombocythaemia
    • Wagstaff AJ, Keating GM. Anagrelide: a review of its use in the management of essential thrombocythaemia. Drugs 2006;66(1):111-31
    • (2006) Drugs , vol.66 , Issue.1 , pp. 111-131
    • Wagstaff, A.J.1    Keating, G.M.2
  • 44
    • 84929167678 scopus 로고    scopus 로고
    • Phase i study results of a novel controlled-release formulation of anagrelide (GALE-401) for the treatment of thrombocytosis
    • Laliberte R GP, Hamilton B. Phase I study results of a novel controlled-release formulation of anagrelide (GALE-401) for the treatment of thrombocytosis. Blood ASH Abstracts 2014;124:21
    • (2014) Blood ASH Abstracts , vol.124 , pp. 21
    • Laliberte, R.G.P.1    Hamilton, B.2
  • 45
    • 84889044017 scopus 로고    scopus 로고
    • Successful long-term treatment of Philadelphia chromosome-negative myeloproliferative neoplasms with combination of hydroxyurea and anagrelide
    • Ahn IE, Natelson E, Rice L. Successful long-term treatment of Philadelphia chromosome-negative myeloproliferative neoplasms with combination of hydroxyurea and anagrelide. Clin Lymphoma Myeloma Leuk 2013;13(Suppl 2):S300-4
    • (2013) Clin Lymphoma Myeloma Leuk , vol.13 , pp. S300-S304
    • Ahn, I.E.1    Natelson, E.2    Rice, L.3
  • 46
    • 0022703490 scopus 로고
    • Therapeutic recommendations in polycythemia vera based on Polycythemia Vera Study Group protocols
    • Berk PD, Goldberg JD, Donovan PB, et al. Therapeutic recommendations in polycythemia vera based on Polycythemia Vera Study Group protocols. Semin Hematol 1986;23(2):132-43
    • (1986) Semin Hematol , vol.23 , Issue.2 , pp. 132-143
    • Berk, P.D.1    Goldberg, J.D.2    Donovan, P.B.3
  • 47
    • 84922917634 scopus 로고    scopus 로고
    • Target hematologic values in the management of essential thrombocythemia and polycythemia vera
    • Hernandez-Boluda JC, Gomez M. Target hematologic values in the management of essential thrombocythemia and polycythemia vera. Euro J Haematol 2015;94(1):4-1
    • (2015) Euro J Haematol , vol.94 , Issue.1 , pp. 4-1
    • Hernandez-Boluda, J.C.1    Gomez, M.2
  • 48
    • 84909584695 scopus 로고    scopus 로고
    • JAK2 inhibitors do not affect stem cells present in the spleens of patients with myelofibrosis
    • Wang X, Ye F, Tripodi J, et al. JAK2 inhibitors do not affect stem cells present in the spleens of patients with myelofibrosis. Blood 2014;124(19):2987-95
    • (2014) Blood , vol.124 , Issue.19 , pp. 2987-2995
    • Wang, X.1    Ye, F.2    Tripodi, J.3
  • 49
    • 84863393110 scopus 로고    scopus 로고
    • A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis
    • Verstovsek S, Mesa RA, Gotlib J, et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med 2012;366(9):799-807
    • (2012) N Engl J Med , vol.366 , Issue.9 , pp. 799-807
    • Verstovsek, S.1    Mesa, R.A.2    Gotlib, J.3
  • 50
    • 84857837774 scopus 로고    scopus 로고
    • JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis
    • Harrison C, Kiladjian JJ, Al-Ali HK, et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med 2012;366(9):787-98
    • (2012) N Engl J Med , vol.366 , Issue.9 , pp. 787-798
    • Harrison, C.1    Kiladjian, J.J.2    Al-Ali, H.K.3
  • 51
    • 84893733177 scopus 로고    scopus 로고
    • A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 Inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea
    • Verstovsek S, Passamonti F, Rambaldi A, et al. A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 Inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea. Cancer 2014;120(4):513-20
    • (2014) Cancer , vol.120 , Issue.4 , pp. 513-520
    • Verstovsek, S.1    Passamonti, F.2    Rambaldi, A.3
  • 52
    • 84928476375 scopus 로고    scopus 로고
    • Ruxolitinib versus standard therapy for the treatment of polycythemia vera
    • Vannucchi AM, Kiladjian JJ, Griesshammer M, et al. Ruxolitinib versus standard therapy for the treatment of polycythemia vera. N Engl J Med 2015;372(5):426-35
    • (2015) N Engl J Med , vol.372 , Issue.5 , pp. 426-435
    • Vannucchi, A.M.1    Kiladjian, J.J.2    Griesshammer, M.3
  • 53
    • 84892882122 scopus 로고    scopus 로고
    • Ruxolitinib is a potent immunosuppressive compound: Is it time for anti-infective prophylaxis?
    • Heine A, Brossart P, Wolf D. Ruxolitinib is a potent immunosuppressive compound: is it time for anti-infective prophylaxis? Blood 2013;122(23):3843-4
    • (2013) Blood , vol.122 , Issue.23 , pp. 3843-3844
    • Heine, A.1    Brossart, P.2    Wolf, D.3
  • 54
    • 20144389274 scopus 로고    scopus 로고
    • Acute leukemia in polycythemia vera: An analysis of 1638 patients enrolled in a prospective observational study
    • Finazzi G, Caruso V, Marchioli R, et al. Acute leukemia in polycythemia vera: an analysis of 1638 patients enrolled in a prospective observational study. Blood 2005;105(7):2664-70
    • (2005) Blood , vol.105 , Issue.7 , pp. 2664-2670
    • Finazzi, G.1    Caruso, V.2    Marchioli, R.3
  • 55
    • 84922264206 scopus 로고    scopus 로고
    • Busulfan in patients with polycythemia vera or essential thrombocythemia refractory or intolerant to hydroxyurea
    • Alvarez-Larran A, Martinez-Aviles L, Hernandez-Boluda JC, et al. Busulfan in patients with polycythemia vera or essential thrombocythemia refractory or intolerant to hydroxyurea. Ann Hematol 2014;93(12):2037-43
    • (2014) Ann Hematol , vol.93 , Issue.12 , pp. 2037-2043
    • Alvarez-Larran, A.1    Martinez-Aviles, L.2    Hernandez-Boluda, J.C.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.